单克隆抗体和多发性骨髓瘤：这一切是否仅仅是另一个挡箭牌？
Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?
机构信息
Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
出版信息
Oncologist. 2018 May;23(5):511-515. doi: 10.1634/theoncologist.2018-0097. Epub 2018 Apr 26.
Abstract
This commentary offers insight about the recent review by the European Medicines Agency on the approval of daratumumab for the treatment of adult patients with multiple myeloma.
摘要
本文就近期欧洲药品管理局（EMA）对达雷妥尤单抗（daratumumab）治疗多发性骨髓瘤（MM）成年患者的审批进行了评估，并提供了相关见解。
相似文献
1
Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?单克隆抗体和多发性骨髓瘤：这一切是否仅仅是另一个挡箭牌？
Oncologist. 2018 May;23(5):511-515. doi: 10.1634/theoncologist.2018-0097. Epub 2018 Apr 26.
2
Incorporating monoclonal antibodies into the management of multiple myeloma.将单克隆抗体纳入多发性骨髓瘤的治疗中。
Clin Adv Hematol Oncol. 2017 Dec;15(12):919-922.
3
Evolution of monoclonal antibodies in multiple myeloma.多发性骨髓瘤中单克隆抗体的演变
Lancet Oncol. 2018 Dec;19(12):1554-1555. doi: 10.1016/S1470-2045(18)30647-8. Epub 2018 Nov 12.
4
Infectious and immunological sequelae of daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的感染性和免疫性后遗症
Br J Haematol. 2019 Apr;185(1):187-189. doi: 10.1111/bjh.15433. Epub 2018 Jul 5.
5
Current use of monoclonal antibodies in the treatment of multiple myeloma.目前在多发性骨髓瘤治疗中使用的单克隆抗体。
Br J Haematol. 2018 May;181(4):447-459. doi: 10.1111/bjh.15121. Epub 2018 Apr 25.
6
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.接受单克隆抗体isatuximab治疗的多发性骨髓瘤患者的体内疫苗接种效果。
Leukemia. 2020 Jan;34(1):317-321. doi: 10.1038/s41375-019-0536-3. Epub 2019 Aug 13.
7
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.多发性骨髓瘤中单克隆抗体和检查点阻断治疗的临床和药理学特征。
Curr Med Chem. 2019;26(32):5968-5981. doi: 10.2174/0929867325666180514114806.
8
Advancement in monoclonal antibody therapy for multiple myeloma.多发性骨髓瘤单克隆抗体治疗的进展。
Lancet Haematol. 2020 May;7(5):e354-e355. doi: 10.1016/S2352-3026(20)30098-3. Epub 2020 Mar 23.
9
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.多发性骨髓瘤中的单克隆抗体：当前和新兴的靶点及作用机制。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101143. doi: 10.1016/j.beha.2020.101143. Epub 2020 Jan 11.
10
Monoclonal antibodies as an addition to current myeloma therapy strategies.单克隆抗体作为当前骨髓瘤治疗策略的一种补充。
Expert Rev Anticancer Ther. 2021 Jan;21(1):33-43. doi: 10.1080/14737140.2021.1837627. Epub 2020 Oct 26.
本文引用的文献
1
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).达雷妥尤单抗单药治疗中危或高危冒烟型多发性骨髓瘤患者的随机、开放标签、多中心、2 期研究（CENTAURUS）。
Leukemia. 2020 Jul;34(7):1840-1852. doi: 10.1038/s41375-020-0718-z. Epub 2020 Feb 5.
2
Ninety-minute daratumumab infusion is safe in multiple myeloma.90分钟的达雷妥尤单抗输注在多发性骨髓瘤中是安全的。
Leukemia. 2018 Nov;32(11):2495-2518. doi: 10.1038/s41375-018-0120-2. Epub 2018 Mar 31.
3
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.EMA 对达雷妥尤单抗治疗多发性骨髓瘤成人患者的评估。
Oncologist. 2018 May;23(5):594-602. doi: 10.1634/theoncologist.2017-0328. Epub 2018 Jan 25.
4
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.复发和难治性多发性骨髓瘤的治疗：新型药物、抗体、免疫疗法及其他。
Leukemia. 2018 Feb;32(2):252-262. doi: 10.1038/leu.2017.329. Epub 2017 Nov 16.
5
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗未经治疗的多发性骨髓瘤。
N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.
6
Management of multiple myeloma in the relapsed/refractory patient.复发性/难治性多发性骨髓瘤的治疗。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):508-517. doi: 10.1182/asheducation-2017.1.508.
7
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.从移植到新型细胞疗法治疗多发性骨髓瘤：欧洲骨髓瘤网络指南和未来展望。
Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7.
8
CD38 antibodies in multiple myeloma: back to the future.多发性骨髓瘤中的 CD38 抗体：回到未来。
Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8.
9
Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).联合 Bcl-2 抑制与 Venetoclax 治疗伴 t（11；14）的难治性原发性浆细胞白血病。
Eur J Haematol. 2018 Feb;100(2):215-217. doi: 10.1111/ejh.12986. Epub 2017 Nov 16.
10
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Venetoclax 作为靶向治疗复发/难治性 t(11;14)多发性骨髓瘤的疗效。
Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.
Zotero 插件